Compare XPOF & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | KPTI |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 172.6M |
| IPO Year | 2021 | 2013 |
| Metric | XPOF | KPTI |
|---|---|---|
| Price | $7.21 | $8.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $8.13 | ★ $14.67 |
| AVG Volume (30 Days) | 406.2K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.24 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $11,092,000.00 | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.91 | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $3.83 | $3.65 |
| 52 Week High | $11.14 | $10.99 |
| Indicator | XPOF | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 61.64 |
| Support Level | $6.81 | $5.84 |
| Resistance Level | $8.32 | $9.00 |
| Average True Range (ATR) | 0.42 | 0.62 |
| MACD | 0.08 | 0.31 |
| Stochastic Oscillator | 74.87 | 88.62 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).